KCI Biotech and its wholly-owned subsidiaries KMQ Biotech and KAL Biotech are CRO companies focused on providing preclinical pharmacology and drug evaluation technical services for pharmaceutical research and development. The company has internationally advanced laboratory animal facilities certified by AAALAC in Suzhou and Nantong, with a total area of over 40,000m2 capabilities for meeting the needs of various preclinical experimental studies. The company has a comprehensive experimental animal platform including mice, rats, hamsters, guinea pigs, rabbits, cats, ferrets, dogs, pigs, sheep, and non-human primates. The company has in vivo pharmacology evaluation system with 500 different animal disease models; BSL2/ABSL2 anti-infection research and development service platform services more than 100 different pathogenic microorganisms (bacteria, viruses, and fungi) essential for human drugs, veterinary drugs, and pet drug development research. It also has multiple service platforms for pathology, toxicology, pharmacokinetics, cell and molecular biology, as well as medical imaging system, and has cooperated with 1,000 well-known domestic and international pharmaceutical companies, completing more than 200 domestic and international new drug registration projects.
KCI/KMQ/KAL, leveraging a professional integrated R&D team, rich experience in in vivo pharmacology and pharmacodynamics evaluation, and a spirit of integrity and excellence, provides comprehensive preclinical new drug R&D services for global pharmaceutical companies and research institutions, establishing a professional and efficient drug development evaluation system.
